NCT00425347已完成1 期
Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Subjects With Advanced Multiple Myeloma
Facet Biotech16 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2006年12月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
- 试验地点
- 16
- 主要终点
- Not applicable for this trial.
研究概览
简要总结
To identify the MTD of HuLuc63 administered intravenously (IV) for 4 doses.2. To evaluate the safety of HuLuc63 IV given every other week for 4 doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:
- •Males or females, age 18 years or older.
- •Diagnosis of advanced multiple myeloma, after at least 2 prior therapies for MM.
- •Measurable disease M component in serum (at least 0.5 G/dL) and/or urine (≥0.2 g excreted in a 24-hour collection sample).
- •Not eligible for stem cell or bone marrow transplant or have refused stem cell or bone marrow transplant or have relapsed after autologous or allogeneic stem cell or bone marrow transplant.
- •ECOG performance status 0-2 (Appendix E).
- •ALT or AST ≤3 x ULN.
- •Total bilirubin ≤2 x ULN (unless related to MM).
- •Serum creatinine ≤2.0 mg/dL (unless related to MM, then ≤ 3.0 mg/dL).
- •Must have adequate bone marrow function defined as: Absolute neutrophil count >1,000 cells/mm3; platelets ≥75,000 cells/mm3; and hemoglobin ≥8 g/dL. No platelet transfusion within 72 hours of obtaining screening platelet count.
- •Serum calcium (corrected for albumin) level within normal range (treatment of hypercalcemia is allowed and subject may enroll if hypercalcemia returns to normal with treatment).
- •Signed and dated informed consent.
- •Use of appropriate contraception where applicable.
- •Negative pregnancy test within 48 hours prior to first dose in women of childbearing potential.
- •Must have 2-dimensional echocardiogram or MUGA indicating LVEF ≥ 45% within 30 days prior to first dose of study drug.
- •Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy regulations).
排除标准
- •Subjects will be ineligible for this study if they meet any one of the following criteria:
- •Life expectancy of less than 3 months.
- •Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for at least 5 years.
- •Plasma cell leukemia (active or prior).
- •Uncontrolled medical problems such as diabetes mellitus, coronary artery disease, hypertension, unstable angina, arrhythmias, pulmonary, hepatic, and renal diseases unless renal insufficiency is felt to be secondary to multiple myeloma (serum creatinine > 2.0 mg/dL).
- •Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia.
- •Corticosteroid, Velcade® or other proteosome inhibitor, thalidomide, lenalidomide (Revlimid®), or melphalan within 2 weeks of the first dose of HuLuc63; nitrogen mustard agents within 6 weeks of the first dose of HuLuc
- •Investigational drug within 4 weeks or 5 half-lives (whichever is greater) of the first dose of HuLuc
- •Stem cell or bone marrow transplant within 12 weeks prior to the first dose of HuLuc
- •Biological agents including intravenous immune globulin (IVIG) and monoclonal antibodies within 4 weeks of the first dose of HuLuc
- •Neuropathy >Grade 2 (according to the NCI CTCAE v3.0 criteria scale).
- •Symptomatic orthostatic hypotension.
- •Evidence of amyloidosis.
- •Known active infections requiring antibiotics, antivirals, or antifungals.
- •Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse follow-up evaluation.
- •Hypersensitivity to recombinant proteins or excipients in the investigational agent.
- •Any condition that in the investigator's opinion makes the subject unsuitable for study participation.
结局指标
主要结局
Not applicable for this trial.
时间窗: Not applicable for this trial.
次要结局
未报告次要终点
研究者
研究点 (16)
Loading locations...
相似试验
已完成
1 期
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT00794781Eisai Inc.55
Unknown
2 期
Adrecizumab Dose Escalation Safety and Tolerability Evaluation (ADESTE)Acute Heart FailureNCT04252937GREAT Network Italy30
终止
2 期
Phase I/II Trial to Investigate BI 836858 in Myelodysplastic SyndromesMyelodysplastic SyndromesNCT02240706Boehringer Ingelheim27
已完成
1 期
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or LymphomasAdvanced Solid TumorsLymphomasNCT01512758Millennium Pharmaceuticals, Inc.36
已完成
1 期
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid TumorsSolid TumorsNCT01862328Millennium Pharmaceuticals, Inc.64